Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLISSc-ILD: Subcutaneous belimumab in adults with systemic sclerosis-associated interstitial lung disease
jRCT2031230153Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and diffuse cutaneous systemic sclerosis (dcSSc) comparing Belimumab SC with Placebo SC (2 arms). Primary endpoint: Absolute change from baseline in FVC (mL) at Week 52. Started Jun 2023; status: recruiting.
02
Drugs
belimumab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on jRCT2031230153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230153.